AIM
TCRT icon

Advantage Investment Management’s Alaunos Therapeutics TCRT Stock Holding History

Advantage Investment Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$6K Hold
10
– – ﹤0.01% 746
2019
Q2 		$9K Hold
10
– – 0.01% 683
2019
Q1 		$6K Hold
10
– – ﹤0.01% 743
2018
Q4 		$3K Buy
+10
New +$3.95K ﹤0.01% 869
2018
Q2 		– Sell
-1
Closed – – 1030
2018
Q1 		$0 Hold
1
– – ﹤0.01% 1060
2017
Q4 		$0 Hold
1
– – ﹤0.01% 1070
2017
Q3 		$1K Hold
1
– – ﹤0.01% 1004
2017
Q2 		$1K Hold
1
– – ﹤0.01% 1043
2017
Q1 		$1K Sell
1
-4
-80% -$3.73K ﹤0.01% 950
2016
Q4 		$4K Buy
5
+4
+400% +$3.6K ﹤0.01% 783
2016
Q3 		$1K Hold
1
– – ﹤0.01% 887
2016
Q2 		$1K Hold
1
– – ﹤0.01% 844
2016
Q1 		$1K Sell
1
-3
-75% -$3.07K ﹤0.01% 837
2015
Q4 		$5K Buy
4
+3
+300% +$4.96K ﹤0.01% 691
2015
Q3 		$2K Buy
+1
New +$1.65K ﹤0.01% 759
2015
Q2 		– Sell
-2
Closed -$3.1K – 910
2015
Q1 		$3K Sell
2
-1
-33% -$1.48K ﹤0.01% 752
2014
Q4 		$3K Buy
+3
New +$1.59K ﹤0.01% 677

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Advantage Investment Management's TCRT Position: Q3 2019 in Review

Advantage Investment Management held its Alaunos Therapeutics (TCRT) position steady in Q3 2019 at 10 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #746.

Advantage Investment Management first reported a position in TCRT in Q4 2014 and has held it in 17 quarters since. The position peaked at $9K in Q2 2019. 142 funds tracked by Wall St. Rank hold TCRT as of Q3 2019.

  • Advantage Investment Management held 10 shares of Alaunos Therapeutics worth $6K as of Q3 2019.
  • Advantage Investment Management left its Alaunos Therapeutics share count unchanged in Q3 2019.
  • Alaunos Therapeutics made up ﹤0.01% of Advantage Investment Management's portfolio in Q3 2019, its #746 holding.
  • Advantage Investment Management first reported a position in Alaunos Therapeutics in Q4 2014 and has held it in 17 quarters since.
  • Advantage Investment Management's Alaunos Therapeutics position peaked at $9K in Q2 2019.
  • 142 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.